Colon, a forgotten site of human xenobiotic metabolism?

Anna-Marja Aura, Ismo Mattila, Tuulikki Seppänen-Laakso, Matej Oresic, Kirsi-Marja Oksman-Caldentey

Research output: Chapter in Book/Report/Conference proceedingConference abstract in proceedingsScientific

Abstract

Human colon contains 1.5 kg of microbiota, which actively takes part in the degradation and decomposition of the non-absorbable intake. This is common knowledge in the dietary fibre research. The concept of dietary fibre complex was proposed in 1984 including polysaccharides and ubiquitous phenolic compounds entrapped into the plant matrix. These phenolic compounds include flavonoids, phenolic acids, tannins, stilbenes and plant lignans, of which lignans are the most studied in terms of microbial metabolism in the colon. Furthermore, there is strong evidence on correlation between their intake, plasma concentration of microbial metabolites, enterodiol (END) and enterolactone (ENL), and reduced risk of chronic diseases. Colonic microbiota changes by age, diet, intestinal diseases and medication causing intra-individual variation in the metabolite pool in addition to the inter-individual variation between subjects. To address these challenges, the developed batch in vitro colon model can be coupled with an advanced metabolomics and bioinformatics platform to provide data on the circulating metabolites. This work has recently been performed for flavan-3-ol stereoisomers, (+)-catechin and (-)-epicatechin. A good correlation has been found for dietary phenolic microbial metabolites between the in vitro colon model and corresponding metabolite profiles from human body fluids. In pharmaceutical research colon has been considered only as an excretion route for non-absorbable drug remnants. Only few companies include microbial metabolism in their drug development and authorities have not given guidelines in this respect. In the case of statins, a cholesterol lowering drug, Simvastatin causes alteration in the pro-inflammatory pathways and in high doses the risk of statin induced myopathy increases. Major portion of Simvastatin is excreted via faeces and thus its adverse effects may be connected with yet unkown colonic metabolites, which identification is attempted.
Original languageEnglish
Title of host publicationPlants for Human Health in the Post-Genome Era
Subtitle of host publicationPSE Congress
EditorsAnnemari Kuokka-Ihalainen, Kirsi-Marja Oksman-Caldentey, Heiko Rischer, Anneli Ritala
Place of PublicationEspoo
PublisherVTT Technical Research Centre of Finland
Pages22-22
ISBN (Electronic)978-951-38-6322-7
ISBN (Print)978-951-38-6321-0 978-951-38-6322-7
Publication statusPublished - 2007
EventPSE Congress: Plants for Human Health in the Post-Genome Era - Helsinki, Finland
Duration: 26 Aug 200729 Aug 2007

Publication series

SeriesVTT Symposium
Number249
ISSN0357-9387

Conference

ConferencePSE Congress: Plants for Human Health in the Post-Genome Era
CountryFinland
CityHelsinki
Period26/08/0729/08/07

Fingerprint Dive into the research topics of 'Colon, a forgotten site of human xenobiotic metabolism?'. Together they form a unique fingerprint.

  • Cite this

    Aura, A-M., Mattila, I., Seppänen-Laakso, T., Oresic, M., & Oksman-Caldentey, K-M. (2007). Colon, a forgotten site of human xenobiotic metabolism? In A. Kuokka-Ihalainen, K-M. Oksman-Caldentey, H. Rischer, & A. Ritala (Eds.), Plants for Human Health in the Post-Genome Era: PSE Congress (pp. 22-22). [O7] VTT Technical Research Centre of Finland. VTT Symposium, No. 249 http://www.vtt.fi/inf/pdf/symposiums/2007/S249.pdf